secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0001193125-25-016224
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup
--------------------------------------------------------------------------------

- TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.
- Cardiac output increased 17.4%; mean pulmonary artery pressure reduced 15.9% across the total study.
- No serious/severe adverse events, discontinuations, or significant hypotension; well tolerated.
- APEX Phase 2 trial in PH-HFpEF is underway; topline results expected in 2026.
- Data support enrichment of CpcPH patients in APEX; Part B of Phase 1b (PH-HFrEF) starts February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/0001193125-25-016224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/d817477d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-016224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer